Blogs & Articles
GPI thought-leadership, pricing and market access insights. Our blogs, white papers and resources provide the latest strategic insight.
LATEST BLOGS / ARTICLES
FDA deals significant blow to low-priced Chinese oncology drugs
By GPI Global Pricing Innovations |
FDA rejects application for sintilimab in combination with chemotherapy, to deal blow to Eli Lilly and creating additional challenges for low-priced Chinese oncology drugs in the US market.
All
- All
- Articles
- Blogs
- Research